SCHEMBL9519121

SCHEMBL9519121

Nc1ccc(Cl)cc1C(=O)c1cnn[nH]1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.51
FADS1 O60427 2/20 0.47
NOS2 P35228 2/20 0.41
IDO1 P14902 4/20 0.40
GCK P35557 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX15 P16050 1/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP1A2 P05177 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15308436 0.82 ALDH1A1 (0.39) IDO1KMT2AALOX15KDM4ECYP1A2
SCHEMBL343076 0.81 ALDH1A1 (0.49) SMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL9685958 0.78 RECQL (0.53) RECQLFADS1NOS2IDO1GCK
SCHEMBL9540049 0.77 RECQL (0.79) RECQLFADS1NOS2GCKSMN1; SMN2
SCHEMBL9684971 0.77 IDO1 (0.57) RECQLFADS1NOS2IDO1GCK
SCHEMBL9518790 0.74 MAPT (0.49) SMN1; SMN2KMT2AKDM4ECYP1A2MAPT
SCHEMBL9686196 0.74 MAPT (0.61) RECQLFADS1NOS2IDO1SMN1; SMN2
SCHEMBL2616481 0.73 RECQL (0.51) RECQLFADS1NOS2IDO1GCK
SCHEMBL27373824 0.73 RECQL (0.48) RECQLFADS1NOS2IDO1GCK
SCHEMBL344032 0.72 RECQL (0.53) RECQLFADS1NOS2GCKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 US disclosed
EP-0574781-A2 2-Amino-5-heterocyclic-substituted-1,4-benzodiazepines and their use in the treatment of aids F. HOFFMANN-LA ROCHE AG (CH) 1993-12-22 EP disclosed
EP-0491218-A1 Benzodiazepinones F. HOFFMANN-LA ROCHE AG (CH) 1992-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885FADS1 1677/4885NOS2 3908/4885
US-20120014997-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885FADS1 1677/4885NOS2 3908/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885FADS1 1677/4885NOS2 3908/4885
US-20090163498-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 RECQL 4746/4885FADS1 1677/4885NOS2 3908/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 RECQL 4746/4885FADS1 1677/4885NOS2 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.